| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Pedersen S | |
| O'Byrne P | |||
| P2860 | cites work | The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler | Q34345721 |
| A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects | Q34346726 | ||
| Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide | Q34512443 | ||
| Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. | Q40768834 | ||
| The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler | Q41851729 | ||
| Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group | Q42061114 | ||
| An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers | Q42133484 | ||
| Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life | Q53636621 | ||
| P433 | issue | 39 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 1-34 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Allergy | Q2699825 |
| P1476 | title | A comparison of the efficacy and safety of inhaled corticosteroids in asthma | |
| P478 | volume | 52 |
| Q35267839 | A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide |
| Q28363538 | A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA-axis in healthy subjects |
| Q32049879 | A review of budesonide inhalation suspension in the treatment of pediatric asthma |
| Q35427205 | Actual therapeutic management of allergic and hyperreactive nasal disorders |
| Q77755182 | Acute adrenal insufficiency in a patient with asthma after changing from fluticasone propionate to budesonide |
| Q41124263 | Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate |
| Q44927006 | Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate |
| Q90247731 | Benefit:Risk Profile of Budesonide in Obstructive Airways Disease |
| Q34112928 | Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders |
| Q39172654 | Budesonide/cyclodextrin complex-loaded lyophilized microparticles for intranasal application. |
| Q44161807 | Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma |
| Q33976334 | Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group |
| Q34273468 | Children with difficult asthma: a practical approach |
| Q33300580 | Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549) |
| Q73132152 | Comparative clinical effectiveness of long-term controller therapy for asthma |
| Q32019428 | Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler |
| Q44377651 | Cortisone therapy today |
| Q46635733 | Daily inhaled corticosteroid treatment should be prescribed for mild persistent asthma. Pro. |
| Q57796439 | Decrease in asthma mortality rate in Israel from 1991-1995: Is it related to increased use of inhaled corticosteroids? |
| Q33634099 | Difficult asthma: beyond the guidelines |
| Q44071549 | Divergent effect of mometasone on human eosinophil and neutrophil apoptosis |
| Q34345371 | Do inhaled corticosteroids inhibit growth in children? |
| Q34505507 | Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler |
| Q43602366 | Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator |
| Q36316621 | Dry powder inhalers for pulmonary drug delivery |
| Q44789793 | Effect of MX-68 on airway inflammation and hyperresponsiveness in mice and guinea-pigs |
| Q35056185 | Effect of inhaled corticosteroids on glycemic status |
| Q44783755 | Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings |
| Q44478297 | Efficacy and safety of budesonide inhalation powder (Pulmicort Turbuhaler) during 52 weeks of treatment in adults and children with persistent asthma |
| Q44998500 | Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate |
| Q43551421 | Efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma |
| Q34738061 | Efficacy of budesonide in moderate to severe asthma |
| Q73098618 | Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone |
| Q44115648 | Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid |
| Q77499004 | Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids |
| Q35595083 | Expected characteristics of an ideal, all-purpose inhaled corticosteroid for the treatment of asthma |
| Q36158275 | Finding the correct inhaled corticosteroid dose in asthma |
| Q78111934 | Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages |
| Q24241308 | Fluticasone versus placebo for chronic asthma in adults and children |
| Q24245407 | Fluticasone versus placebo for chronic asthma in adults and children |
| Q41775559 | High-dose inhaled corticosteroid use in childhood asthma: an observational study of GP prescribing |
| Q34298218 | Iatrogenic Cushing's syndrome with inhaled steroid plus antidepressant drugs |
| Q42659511 | Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate |
| Q35034104 | Inhaled Corticosteroids Adverse Events In Asthmatic Children: A Review. |
| Q33721468 | Inhaled corticosteroids for adult asthma: impact of formulation and delivery device on relative pharmacokinetics, efficacy and safety |
| Q34995731 | Inhaled corticosteroids in childhood asthma: the story continues |
| Q33801957 | Lesson of the week: right sided aortic arch in children with persistent respiratory symptoms |
| Q44173319 | Long-term outcomes in paediatric asthma |
| Q73435576 | Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma |
| Q44534203 | Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children |
| Q43547471 | Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate |
| Q41693586 | Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children |
| Q33860030 | Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment |
| Q34508586 | Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma |
| Q35801421 | Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma |
| Q50634786 | Osteoporosis in the corticosteroid-treated patient with asthma. |
| Q35569906 | Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids |
| Q24650169 | Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate |
| Q28365894 | Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler |
| Q36578777 | Pharmacological management of mild or moderate persistent asthma |
| Q35595099 | Preclinical properties of budesonide: translation to the clinical setting |
| Q36225318 | Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration |
| Q42603944 | Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma |
| Q73472044 | Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler |
| Q35595091 | Review of the unique properties of budesonide |
| Q85045921 | Safety of inhaled corticosteroids in COPD |
| Q34523194 | Safety of inhaled corticosteroids in children |
| Q35167358 | Safety of the newer inhaled corticosteroids in childhood asthma |
| Q40848064 | Serum Fructosamine, Total Cholesterol, and High-Density Lipoprotein in Children with Asthma during Glucocorticoid Treatment |
| Q39335010 | Short-term safety and tolerability of double-dose salmeterol/fluticasone propionate in adult asthmatic patients |
| Q33543636 | Stressors and concerns in teen asthma |
| Q34161394 | Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom |
| Q77378018 | The effect of intranasal and inhaled corticosteroids in healthy volunteers on the number of circulating lymphocytes and lymphocyte subsets |
| Q30419000 | The effects of inhaled corticosteroids on growth in children |
| Q43713633 | The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design |
| Q51687256 | The role of antileukotrienes in the treatment of asthma. |
| Q35716906 | The role of budesonide in adults and children with mild-to-moderate persistent asthma |
| Q34291204 | The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood |
| Q34994955 | The use of inhaled corticosteroids in adult asthma |
| Q45274547 | The use of sterically stabilized liposomes to treat asthma |
| Q35595096 | Therapeutic margin of budesonide in patients with mild to severe asthma |
| Q31409970 | Transcriptional potencies of inhaled glucocorticoids. |
| Q58712869 | Treating Pediatric Asthma According Guidelines |
| Q35054028 | Vascular Anomalies in Children Misdiagnosed with Asthma: Case series |
| Q83944073 | [Asthma therapy: combination of topical glucocorticosteroids and theophylline] |
| Q83944069 | [Therapy of asthma: anti-inflammatory effects of antileukotrienes] |
Search more.